Biophan Technologies Development Shows Innovation, Says Investrend Affiliate Beacon Research Note.NEW YORK -- (Investrend Research Syndicate) A new research note has been issued by Investrend Research Affiliate Beacon Equity Research analyst Shailesh Dhuri on Biophan Technologies (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BIPH BIPH Bogomoletz Institute of Physiology (National Academy of Sciences; Ukraine) ). The full report is available at http://www.beaconequityresearch.com and http://www.investrendresearch.com In the report, Mr. Dhuri writes, "Biophan Technologies, Inc. provides innovative solutions for making biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. devices safe for use with Magnetic Resonance Imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. ) devices and reduces the interference these devices cause to the quality of MRI images. The mission of Biophan is to redesign the active and passive biomedical devices to make them MRI safe and compatible. Biophan boasts an impressive portfolio of a total of 114 U.S. patents, licenses, or applications, which includes 36 issued U.S. patents, 6 recently-allowed applications that will be issued as patents in the near future, and 72 pending applications. "Biophan has successfully tested its patented technology that enables MRI within vascular stents, allowing physicians for the first time to assess the health of arteries using stents by means of non-invasive MRI technology. "Biophan needs to enter into strategic partnerships, or similar such arrangements, to unlock the full value of its patent portfolio. A partnership with a company with deep pockets and expertise in the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. regulatory process would reduce the time to bring to market its technological applications. The costs to bring biomedical devices to market can be quite high, and the Company needs to reach a favorable agreement with a large manufacturer to ensure its success. "This recent announcement further demonstrates that Biophan is continuing to develop new, innovative products based on its market-leading patent portfolio," the analyst concluded. Beacon Equity Research, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control is a fee-based, comprehensive investment research firm, focusing primarily on the underserved small-cap sector. All Beacon analysts are seasoned industry professionals and adhere to the CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. Institute's (CFAI CFAI Commission on Fire Accreditation International CFAI Central Florida Autism Institute ) stringent ethics and standards of practice guidelines. Beacon Research does not have any investment banking relationships with any of the companies covered. All analysts are compensated prior to performing their investment research and are not compensated in any way based on the future performance of the equities they follow. " Both Beacon Equity Research and Investrend subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com. Beacon Research has been compensated a total of $18,000 by Biophan Technologies for a one-year enrolment in its research program. Complete information is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes,. Investors are advised to read disclosures carefully before trading in the equities of any enrolled company. Anyone interested in receiving alerts regarding Biophan Technologies research should email contact@investrend.com with "BIPH" in the subject line. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion